Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK)
- Previous Close
0.510 - Open
0.520 - Bid 0.510 x --
- Ask 0.520 x --
- Day's Range
0.510 - 0.520 - 52 Week Range
0.490 - 0.830 - Volume
2,878,000 - Avg. Volume
7,545,285 - Market Cap (intraday)
4.852B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.010 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield 0.04 (7.45%)
- Ex-Dividend Date Jun 6, 2023
- 1y Target Est
2.74
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China. It offers drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology and technology promotion, and medical aesthetic research and development services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.
www.sihuanpharm.com2,872
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0460.HK
Performance Overview: 0460.HK
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0460.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0460.HK
Valuation Measures
Market Cap
4.76B
Enterprise Value
1.31B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.36
Price/Book (mrq)
0.99
Enterprise Value/Revenue
0.71
Enterprise Value/EBITDA
12.14
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.90%
Return on Assets (ttm)
-0.72%
Return on Equity (ttm)
-4.78%
Revenue (ttm)
1.86B
Net Income Avi to Common (ttm)
-54.02M
Diluted EPS (ttm)
-0.010
Balance Sheet and Cash Flow
Total Cash (mrq)
4.37B
Total Debt/Equity (mrq)
24.36%
Levered Free Cash Flow (ttm)
--
Research Analysis: 0460.HK
Company Insights: 0460.HK
0460.HK does not have Company Insights